ライフサイエンスコーパス: cytomegalovirus

1 ctions with HIV, hepatitis C virus, or human cytomegalovirus).

2 ex, HLA type, or previous exposure to EBV or cytomegalovirus.

3 efforts to decrease the effect of congenital cytomegalovirus.

4 rget for antiviral development against human cytomegalovirus.

5 are always serologically positive for human cytomegalovirus.

6 oth inflammasome and IFN-I to control murine cytomegalovirus.

7 virus, but dispensable in the case of mouse cytomegalovirus.

8 dependent after viral challenge with murine cytomegalovirus.

9 vented necroptosis upon infection with mouse cytomegalovirus.

10 nt of opportunistic infections (OI), such as cytomegalovirus.

11 hallmark of the cytopathic effect induced by cytomegaloviruses.

12 on, we have analyzed an infection with mouse cytomegalovirus, a persistent-latent virus that elicits

13 ange of viral infections including BK virus, cytomegalovirus, adenovirus, human herpesvirus 6, and Ep

14 circuits in HIV-1 and the human herpesvirus cytomegalovirus along with potential circuit-disruption

15 One patient developed cytomegalovirus and BK and 2 others EBV and BK viremia.

16 AIM2 activators Francisella novicida, mouse cytomegalovirus and DNA, and the infectious agents Liste

17 Alignment of HSV UL37 with the human cytomegalovirus and Epstein-Barr virus UL37 homologs rev

18 ings help explain the broad tropism of human cytomegalovirus and indicate that PDGFRalpha and the vir

19 multiple, unrelated pathogenic viruses such Cytomegalovirus and Influenza A (H1N1).

20 latter indicates the involvement of HSV1 and cytomegalovirus (and the necessity of taking into accoun

21 es 1 and 2, Epstein-Barr virus, enterovirus, cytomegalovirus, and chikungunya virus).

22 svirus family: varicella zoster virus, human cytomegalovirus, and Epstein-Barr virus.

23 llis, varicella-zoster, and parvovirus B19), cytomegalovirus, and herpes simplex virus.

24 virus, HIV, varicella zoster virus, Rubella, Cytomegalovirus, and Herpesviruses are a major cause of

25 HBV, and 1 case each of HBV, parvovirus B19, cytomegalovirus, and human herpesvirus 7).

26 eveloping fetus (i.e., Zika virus, brucella, cytomegalovirus, and toxoplasma).

27 Cumulative incidences of graft failure, cytomegalovirus, and/or adenoviral infections and transp

28 ytokine IL-12 was added, which also affected cytomegalovirus- and Epstein-Barr virus-specific T cells

29 c substitutions did not confer resistance to cytomegalovirus antivirals in vitro, suggesting that the

30 We used quantitative PCR to test for cytomegalovirus, BK polyomavirus, human herpesvirus 6B,

31 ificantly lower rates of avascular necrosis, cytomegalovirus, cataracts, new-onset diabetes after tra

32 Importance: Congenital cytomegalovirus (cCMV) infection is a major cause of chi

33 Risk of congenital cytomegalovirus (cCMV) transmission is highly dependent

34 knowledge of the epidemiology of congenital cytomegalovirus (cCMV) with the type of maternal infecti

35 Cytomegalovirus (CMV) acquisition and inflammation were

36 Anti-cytomegalovirus (CMV) activity was assessed in 280 pretr

37 thesized that the presence of replication of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) (the

38 Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are t

39 Such is the case for cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infec

40 Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infec

41 y, we investigated the effect of subclinical cytomegalovirus (CMV) and Epstein-Barr virus (EBV) repli

42 Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) were

43 Patients seropositive for cytomegalovirus (CMV) and undergoing allogeneic haemopoi

44 Although cytomegalovirus (CMV) antibody titers were higher in cas

45 unmasking of cryptotopes by unfolding whole cytomegalovirus (CMV) antigen preparations with the chao

46 oliferate when exposed to superantigen or to cytomegalovirus (CMV) antigen using matched T cells and

47 Human cytomegalovirus (CMV) antigens have been identified in G

48 nstructing an rMVA encoding 3 immunodominant cytomegalovirus (CMV) antigens, which stimulates a host

49 Infection with cytomegalovirus (CMV) can elicit a CD8(+) T cell respons

50 Persistent infections with cytomegalovirus (CMV) differentially affect the host imm

51 nous ganciclovir and oral valganciclovir for cytomegalovirus (CMV) disease in solid organ transplant

52 Whether cytomegalovirus (CMV) DNA exists in plasma as virion-ass

53 The kinetics of cytomegalovirus (CMV) DNA in infected asymptomatic hosts

54 Interassay harmonization of cytomegalovirus (CMV) DNA measurement is important for i

55 Quantitative cytomegalovirus (CMV) DNA-specific polymerase chain reac

56 Cytomegalovirus (CMV) entry into fibroblasts differs fro

57 The prototypic betaherpesvirus human cytomegalovirus (CMV) establishes life-long persistence

58 Cytomegalovirus (CMV) IgG antibodies have been associate

59 Cytomegalovirus (CMV) infection and disease are importan

60 s is exacerbated in patients with concurrent cytomegalovirus (CMV) infection and inflammatory bowel d

61 es in a comparison group) revealed prevalent cytomegalovirus (CMV) infection at diagnosis in childhoo

62 We explored the role of cytomegalovirus (CMV) infection in CD8 lymphocytosis and

63 Congenital cytomegalovirus (CMV) infection is a leading cause of me

64 Cytomegalovirus (CMV) infection is a significant complic

65 Antiviral-resistant or refractory cytomegalovirus (CMV) infection is challenging, and salv

66 The immune response to cytomegalovirus (CMV) infection is highly complex, inclu

67 Cytomegalovirus (CMV) infection is one of the most commo

68 Cytomegalovirus (CMV) infection is the most prevalent in

69 Persistent herpesvirus infections including cytomegalovirus (CMV) infection may be particularly impo

70 Cytomegalovirus (CMV) infection negatively influences bo

71 Cytomegalovirus (CMV) infection sometimes causes large e

72 pathways contribute to the control of early cytomegalovirus (CMV) infection, leading to a multiphasi

73 ifferentiated NK cell subsets in response to cytomegalovirus (CMV) infection, paralleling antigen-spe

74 Cytomegalovirus (CMV) is a highly complex pathogen which

75 Cytomegalovirus (CMV) is a major contributor to morbidit

76 ization or passive administration.IMPORTANCE Cytomegalovirus (CMV) is a significant cause of birth de

77 Cytomegalovirus (CMV) is a ubiquitous human pathogen tha

78 Cytomegalovirus (CMV) is acquired by the oral route in c

79 Ganciclovir-resistant (ganR) cytomegalovirus (CMV) is an emerging and important probl

80 Cytomegalovirus (CMV) is associated with morbidity and m

81 Cytomegalovirus (CMV) is one of the most common viral pa

82 Although initial therapy for cytomegalovirus (CMV) is usually successful, a significa

83 The replication cycle of human cytomegalovirus (CMV) leads to drastic reorganization of

84 The influence of cytomegalovirus (CMV) on recurrent hepatitis C virus (HC

85 racteristics, and persistent infections with cytomegalovirus (CMV) or EBV.

86 Cytomegalovirus (CMV) persists in most humans, requires

87 n association between early (before day 100) cytomegalovirus (CMV) reactivation and decreased inciden

88 transplant (allo-HCT) recipients at risk for cytomegalovirus (CMV) reactivation from those who are no

89 The role of cytomegalovirus (CMV) reactivation in mediating adverse

90 Infection and disease caused by human cytomegalovirus (CMV) remain a significant burden in pat

91 Cytomegalovirus (CMV) replication and disease, with its

92 To evaluate the rates of new-onset cytomegalovirus (CMV) retinitis and worsening existing C

93 The incidence of cytomegalovirus (CMV) retinitis in the pediatric allogen

94 T cell repertoire of 666 subjects with known cytomegalovirus (CMV) serostatus by immunosequencing.

95 Cytomegalovirus (CMV) urinary shedding in pregnant women

96 sus, Streptococcus viridians bacteremia, and cytomegalovirus (CMV) viremia and identified mutations i

97 The observed cytomegalovirus (CMV) viremia rate for patients at risk

98 minister long courses of prophylaxis against cytomegalovirus (CMV) without evidence of benefit and wi

99 ection for each herpesvirus were as follows: cytomegalovirus (CMV), 44%; human herpesvirus [HHV] 6, 1

100 adenovirus, EBV, human herpesvirus 6 (HHV6), cytomegalovirus (CMV), and BK virus screened weekly.

101 ontrol viruses, Epstein-Barr virus (EBV) and cytomegalovirus (CMV), and compared to bulk memory CD8 T

102 Epstein-Barr virus (EBV), adenovirus (AdV), cytomegalovirus (CMV), BK virus (BKV), and human herpesv

103 Cytomegalovirus (CMV), Epstein-Barr virus (EBV), and HHV

104 sting surveys for quantitative PCR assays of cytomegalovirus (CMV), Epstein-Barr virus (EBV), BK viru

105 We studied viremia episodes with cytomegalovirus (CMV), Epstein-Barr virus (EBV), human h

106 d 5 herpesviruses (Epstein Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus types 1 and

107 -15, and IL-18 or in response to antigens or cytomegalovirus (CMV), human and mouse NK cells exhibit

108 , and in some cases exclusively, detected in cytomegalovirus (CMV)- and Epstein-Barr virus (EBV)-resp

109 Cytomegalovirus (CMV)-based vaccines have shown remarkab

110 Recombinant cytomegalovirus (CMV)-based vectors are a novel vaccine

111 Human cytomegalovirus (CMV)-induced adaptive natural killer (N

112 en we measured the CD4(+) T cell response to cytomegalovirus (CMV)-infected dendritic cells in vitro,

113 tudies, we demonstrate that the frequency of cytomegalovirus (CMV)-pp65-specific T-cell responses in

114 This present study aims to examine how cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (

115 Detectable cytomegalovirus (CMV)-specific T cells in CMV-seronegati

116 C virus [HCV], Epstein-Barr virus [EBV], or cytomegalovirus [CMV]) in KTR on sirolimus (SRL) + mycop

117 ation (with varicella-zoster virus [VZV] and cytomegalovirus [CMV]).

118 Vaccination with human cytomegalovirus-derived noninfectious particles, or dens

119 The human cytomegalovirus developed distinct evasion mechanisms fr

120 disease; death was directly attributable to cytomegalovirus disease in three (1%) of 263 patients wh

121 was poor, including increased incidences of cytomegalovirus disease, herpes zoster, BK virus, and ne

122 l antiviral in development for prevention of cytomegalovirus disease.

123 95 patients developed cytomegalovirus disease; death was directly attributable

124 Cytomegalovirus DNA in SOTR plasma is almost exclusively

125 Cytomegalovirus DNA results were highly reproducible for

126 e and is an attractive target for anti-human cytomegalovirus drug development.

127 the interpretation of genotypic testing for cytomegalovirus drug resistance.

128 Therefore, anti-human cytomegalovirus drugs from novel targets are needed for

129 and Drug Administration-approved anti-human cytomegalovirus drugs mainly target the viral polymerase

130 tion with nonintegrin receptors (i.e., human cytomegalovirus EGFR), to dictate species-specific entry

131 We observed that the mouse cytomegalovirus encoded protein m18 is necessary and suf

132 Human cytomegalovirus encodes 2 viral cytokines that are ortho

133 Human cytomegalovirus encodes at least 25 membrane glycoprotei

134 Human cytomegalovirus encodes several immune modulatory protei

135 atient underwent isolated enterectomy due to cytomegalovirus enteritis.

136 coccus pneumoniae, Streptococcus agalactiae, cytomegalovirus, enterovirus, herpes simplex virus 1 and

137 alysis for Herpes simplex, varicella zoster, cytomegalovirus, Epstein-Barr virus and Toxoplasma gondi

138 onotherapy with autologous VSTs specific for cytomegalovirus, Epstein-Barr virus, or adenovirus and g

139 differences in organism density, except with cytomegalovirus, for which there was a higher quantity i

140 Cytomegalovirus genotyping results from a phase 2 trial

141 The human cytomegalovirus glycoprotein gp68 functions as an Fc rec

142 ntion strategy against congenital guinea pig cytomegalovirus (GPCMV) infection.

143 0 (vIL-10) ortholog of both human and rhesus cytomegalovirus (HCMV and RhCMV, respectively) suppresse

144 Human cytomegalovirus (HCMV) acquires its membrane in an intra

145 Human cytomegalovirus (HCMV) activation is associated with dec

146 f infection of certain cell types with human cytomegalovirus (HCMV) and that THY-1 is important for H

147 The genomes of DNA viruses such as human cytomegalovirus (HCMV) are devoid of histones within vir

148 AC) is an important step for efficient human cytomegalovirus (HCMV) assembly.

149 Recent studies have shown that human cytomegalovirus (HCMV) can induce a robust increase in l

150 n the central nervous system caused by human cytomegalovirus (HCMV) congenital infection, the mechani

151 Human cytomegalovirus (HCMV) counteracts host defenses that ot

152 In lung transplant recipients (LTRs), human cytomegalovirus (HCMV) DNA detection in the bronchoalveo

153 Human cytomegalovirus (HCMV) down-regulates PVR expression, bu

154 The DNA virus human cytomegalovirus (HCMV) encodes a viral Cdk (v-Cdk) (the

155 8 locus present in clinical strains of human cytomegalovirus (HCMV) encodes proteins required for lat

156 alizing antibodies (NAb) targeting the human cytomegalovirus (HCMV) envelope pentamer complex (PC) ar

157 for the hematogenous dissemination of human cytomegalovirus (HCMV) following a primary infection.

158 vidence is provided demonstrating that human cytomegalovirus (HCMV) gB depends on the S-palmitoylatio

159 The strict species specificity of Human Cytomegalovirus (HCMV) has impeded our understanding of

160 Expression of the human cytomegalovirus (HCMV) IE1 and IE2 proteins is critical

161 DNA detection of human cytomegalovirus (hCMV) in cerebrospinal fluid (CSF) by p

162 Reactivation of human cytomegalovirus (HCMV) in transplant recipients can caus

163 -stranded RNAs (dsRNA) produced during human cytomegalovirus (HCMV) infection activate the antiviral

164 Human cytomegalovirus (HCMV) infection and periodic reactivati

165 Human cytomegalovirus (HCMV) infection causes disease in newbo

166 Human cytomegalovirus (HCMV) infection causes severe disease a

167 Primary human cytomegalovirus (HCMV) infection during pregnancy is the

168 Congenital human cytomegalovirus (HCMV) infection is a significant cause

169 and are directly antiviral.IMPORTANCE Human cytomegalovirus (HCMV) infection is carried for a lifeti

170 Human cytomegalovirus (HCMV) infection is limited by HCMV-spec

171 the biological impact in patients with human cytomegalovirus (hCMV) infection is not well defined in

172 developing brain.IMPORTANCE Congenital human cytomegalovirus (HCMV) infection is the most common vira

173 Human cytomegalovirus (HCMV) infection of myeloid cells is clo

174 Primary human cytomegalovirus (HCMV) infection usually goes unnoticed,

175 large-scale transcriptome analyses of human cytomegalovirus (HCMV) infection.

176 based on dense bodies (DB) produced by human cytomegalovirus (HCMV) infections, we evaluated scalable

177 Human cytomegalovirus (HCMV) infects over half of the populati

178 Human cytomegalovirus (HCMV) infects peripheral blood monocyte

179 Human cytomegalovirus (HCMV) is a herpesvirus with both lytic

180 Human cytomegalovirus (HCMV) is a large, double-stranded DNA v

181 Human cytomegalovirus (HCMV) is a major human pathogen, causin

182 The human cytomegalovirus (HCMV) is a ubiquitous, human pathogenic

183 Human cytomegalovirus (HCMV) is able to reconfigure the host c

184 Human cytomegalovirus (HCMV) is an enveloped double-stranded D

185 The 235-kilobase genome of human cytomegalovirus (HCMV) is by far the largest of any herp

186 Human cytomegalovirus (HCMV) is the leading cause of congenita

187 Human Cytomegalovirus (HCMV) is the most common cause of child

188 As human cytomegalovirus (HCMV) is the most common infectious cau

189 Human cytomegalovirus (HCMV) is the most common viral infectio

190 Human cytomegalovirus (HCMV) is the prototypical human beta-he

191 In contrast to many viruses, human cytomegalovirus (HCMV) is unable to productively infect

192 The establishment of human cytomegalovirus (HCMV) latency and persistence relies on

193 s series to demonstrate micromolar antihuman cytomegalovirus (HCMV) potency.

194 osphatases for their importance during human cytomegalovirus (HCMV) replication and identified the cl

195 bout the cellular factors required for human cytomegalovirus (HCMV) replication.

196 pacity to block HAdV and, in addition, human cytomegalovirus (HCMV) replications at low micromolar co

197 ex virus 1 (HSV-1) large terminase and human cytomegalovirus (HCMV) small terminase.

198 Clinical human cytomegalovirus (HCMV) strains invariably mutate when pr

199 Human cytomegalovirus (HCMV) strains that have been passaged i

200 The human cytomegalovirus (HCMV) terminase complex consists of sev

201 The human cytomegalovirus (HCMV) US12 family consists of ten seque

202 oses (60, 120, and 240 mg/day) against human cytomegalovirus (HCMV) was evaluated in a recent phase 2

203 others show that microRNAs encoded by human cytomegalovirus (HCMV) were readily detected in human se

204 ic diversity over the entire genome of human cytomegalovirus (HCMV), a significant pathogen for immun

205 While many viruses, including human cytomegalovirus (HCMV), blunt host antiviral defenses by

206 on and action, many viruses, including human cytomegalovirus (HCMV), evade host defenses.

207 aboratory strains (AD169 and Towne) of human cytomegalovirus (HCMV), which are known to use cell memb

208 The human cytomegalovirus (HCMV)-encoded viral cyclin-dependent ki

209 The role of human cytomegalovirus (HCMV)-specific T-cell responses in brea

210 or and inhibits viral DNA replication (human cytomegalovirus [HCMV] and human papillomavirus [HPV]) a

211 nfections that cause substantial impairment: cytomegalovirus, herpes simplex virus, rubella virus, To

212 l diagnosis included toxoplasmosis, rubella, cytomegalovirus, herpes simplex virus, syphilis, and hum

213 al infections, including rubella, congenital cytomegalovirus, human immunodeficiency virus, hepatitis

214 vities to HSV-1 IgG, cytomegalovirus IgM, or cytomegalovirus IgG did not appear to increase gastrosch

215 Reactivities to HSV-1 IgG, cytomegalovirus IgM, or cytomegalovirus IgG did not appe

216 expression cassette under the control of the cytomegalovirus immediate early promoter into the VC2 ve

217 Human cytomegalovirus immediate-early protein pUL37 x 1 induce

218 screening of mothers and the routine use of cytomegalovirus immunoglobulin for prophylaxis or treatm

219 immunological presentation, the presence of cytomegalovirus in some glioblastomas may impact progres

220 nfluenza A virus, herpes simplex virus 1, or cytomegalovirus induced a strong antiviral response meas

221 Congenital toxoplasmosis (CT) and cytomegalovirus infection (cCMV) may cause significant m

222 Most evidence suggests that early cytomegalovirus infection accelerates HIV disease progre

223 Control of cytomegalovirus infection after allo-BMT was also impair

224 d in 47% of patients, with 4 presenting with cytomegalovirus infection and 4 (age, 42-59 years) diagn

225 y was performed using the Spanish Congenital Cytomegalovirus Infection Database.

226 cidofovir to placebo for prophylaxis against cytomegalovirus infection in hematopoietic cell transpla

227 Human cytomegalovirus infection in individuals lacking a fully

228 The effects of cytomegalovirus infection on HIV-exposed infants are poo

229 Gaps remain in understanding the role that cytomegalovirus infection plays in HIV-exposed infants.

230 than groups A (37%) or B (23%) (P < 0.001); cytomegalovirus infection rates were 35%, 20% and 23%, r

231 ta in the literature suggest that congenital cytomegalovirus infection remains a research priority, b

232 the mother increases the rate of congenital cytomegalovirus infection, while maternal antiretroviral

233 haematogenous liver and lung metastasis, and cytomegalovirus infection.

234 K) cells are key mediators in the control of cytomegalovirus infection.

235 Both cytomegalovirus interleukin 10 (cmvIL-10) and Latency-as

236 rleukin 10 (cmvIL-10) and Latency-associated cytomegalovirus interleukin 10 (LAcmvIL-10) (collectivel

237 ere also obtained that indicated that rhesus cytomegalovirus is able to persist due to upregulation o

238 Congenital cytomegalovirus is the most frequent, yet under-recognis

239 reening a panel of deletion mutants of mouse cytomegalovirus (MCMV) a mutant was identified that did

240 e and innate immune cells critical for mouse cytomegalovirus (MCMV) clearance.

241 y contrast, systemic infection with a murine cytomegalovirus (MCMV) engineered to express HEL induced

242 on brain-resident microglia following murine cytomegalovirus (MCMV) infection.

243 imulation and by mouse NK cells during mouse cytomegalovirus (MCMV) infection.

244 ansion and memory cell formation after mouse cytomegalovirus (MCMV) infection.

245 ls were able to respond to a specific murine cytomegalovirus (MCMV) protein and that in the absence o

246 In this study, murine cytomegalovirus (MCMV) was used as a persistent infectio

247 Interrogation of murine cytomegalovirus (MCMV)-encoded cell-death suppressors re

248 This murine cytomegalovirus (MCMV)-encoded protein, m12, restrains N

249 han to another murine betaherpesvirus, mouse cytomegalovirus (MCMV).

250 opositive donor, and underwent weekly plasma cytomegalovirus monitoring by PCR through to day 100 pos

251 Cytomegalovirus occurred at 5.6 (0.63-27.7) months postt

252 The human cytomegalovirus opening reading frame UL144 is an orthol

253 says also revealed positive test results for cytomegalovirus or Epstein-Barr virus, indicating possib

254 Neutrophils pulsed with the cognate antigens cytomegalovirus pp65 or influenza hemagglutinin were abl

255 , as opposed to the conventional approach of cytomegalovirus promoter-driven expression from an episo

256 n level despite transcriptional control by a cytomegalovirus promoter.

257 e excluded because of their participation in cytomegalovirus prophylaxis trials.

258 post-HCT dasatinib use increased the risk of cytomegalovirus reactivation (adjusted hazard ratio, 7.6

259 An informal International Congenital Cytomegalovirus Recommendations Group was convened in 20

260 s pUL89 endonuclease inhibitor blocked human cytomegalovirus replication at a relatively late time po

261 donuclease activity that also inhibits human cytomegalovirus replication in cell culture.

262 n, which have received FDA approval to treat cytomegalovirus retinitis and high blood cholesterol, re

263 ve been reported with dasatinib use, but its cytomegalovirus risk after hematopoietic-cell transplant

264 Across age groups, cytomegalovirus seropositive individuals displayed immun

265 between Jan 1, 2007, and Feb 28, 2013, were cytomegalovirus seropositive or had a seropositive donor

266 an 50 years, performance of a kidney biopsy, cytomegalovirus seropositive status, donation after card

267 ted with higher mortality included recipient cytomegalovirus seropositivity (HR 1.40, 95% CI 1.13-1.7

268 time and associated with increasing age and cytomegalovirus seropositivity.

269 nor characteristics such as sex, parity, and cytomegalovirus serostatus were not associated with surv

270 year overall survival adjusted for recipient cytomegalovirus serostatus, conditioning regimen intensi

271 een donor characteristics (age, sex, parity, cytomegalovirus serostatus, HLA match, and blood group A

272 We have previously shown that the human cytomegalovirus signal-anchored protein known as viral m

273 higher frequencies of regulatory T cells and cytomegalovirus-specific CD4(+) T cells correlated negat

274 Cytomegalovirus-specific CTLs isolated by the IFN-gamma

275 Cytomegalovirus-specific CTLs responded specifically to

276 Toxoplasmosis, rubella, cytomegalovirus, syphilis, and human immunodeficiency vi

277 ic testing ruled out toxoplasmosis, rubella, cytomegalovirus, syphilis, and human immunodeficiency vi

278 The human cytomegalovirus terminase complex cleaves concatemeric g

279 One component of the human cytomegalovirus terminase complex, pUL89, provides the e

280 %) patients were excluded because of missing cytomegalovirus testing and 24 (2%) were excluded becaus

281 For example, in human cytomegalovirus, the nucleotide diversity estimates are

282 be given to universal neonatal screening for cytomegalovirus to facilitate early detection and interv

283 Decreasing cytomegalovirus transmission prenatally and in infancy m

284 Murine cytomegalovirus triggers both apoptosis and necroptosis

285 Diagnostic mutations in the cytomegalovirus UL97 kinase gene are used to assess the

286 te clinical endpoint for clinical trials for cytomegalovirus vaccines, biologics, and drugs.

287 acaque SIV vaccine trial using a recombinant cytomegalovirus vector.

288 that vaccinating rhesus macaques with rhesus cytomegalovirus vectors in which genes Rh157.5 and Rh157

289 e antileukemic responses than UV-inactivated cytomegalovirus, vesicular stomatitis virus, reovirus, o

290 Cytomegalovirus viraemia is associated with an increased

291 erefore investigated the association between cytomegalovirus viral load and mortality in the first ye

292 els were used to estimate the association of cytomegalovirus viral load at different thresholds with

293 Although cytomegalovirus viral load is commonly used to guide pre

294 A cytomegalovirus viral load of 250 IU/mL or greater was a

295 Similar associations were noted for higher cytomegalovirus viral load thresholds.

296 tract infection (cystitis) (34.9% vs 25.2%), cytomegalovirus viremia (17.8% vs 24.2%), flu-like syndr

297 Cytomegalovirus viremia (any and high-level) was more fr

298 iller cells among donors infected with human cytomegalovirus with one or two copies of the allele.

299 flationary effector responses against latent cytomegalovirus with only limited evidence of exhaustion

300 ently reported a replication-defective human cytomegalovirus with restored pentameric complex glycopr